Common Contracts
1 similar Transformative Agreement contracts
BARDA DEAL AND CONFERENCE CALLTransformative Agreement • June 23rd, 2022
Crossject’s agreement with BARDA on ZENEO® Midazolam, potentially worth $155m, is transformative. There was great anticipation around the decision on BARDA’s request for proposals, which was expected in 2022. This announcement is very good news since, despite the company’s solid case, visibility was limited on the timing of the decision, the competition, and the potential amounts. The deal lends credibility to the pipeline of emergency treatments and also significantly enhances the company’s commercial prospects. We expect the 1st shipments to occur in H1 23. After updating our model, we have raised our TP to €6.5 (from €3.2 previously). BUY reiterated.
